Morgan Lewis

Related Publications

07/25/12 FDA User Fee Act Full of Surprises for Pharma and Biotech
FDA user fee reauthorization law expands fees to include generic and biosimilar applications, and includes a new emphasis on drug supply chain safety and incentives for development of new therapies.
02/09/12 FDA Issues Three Draft Guidances for Biosimilars
Initial guidance provides insights on regulatory pathway for biosimilars, but does not address many critical issues.
View all publications

Related News

09/06/11 Former FDA Regulatory Counsel Returns to Morgan Lewis
Morgan Lewis announces that Alexis Reisin Miller has returned to the firm as a partner in its FDA & Healthcare Practice, resident in Washington, D.C.
View all news
Photo of  Alexis Reisin Miller

practice accolades

FDA & Healthcare

Ranked the second-largest U.S. healthcare law firm by Modern Healthcare (2012)

Recognized as a top 10 law firm within the Life Sciences Regulatory Super League by The Practical Law Company (PLC) (2012)

Listed as Recommended in PLC's Life Sciences Multi-Jurisdictional Guide (2012)

bar admissions

  • District of Columbia
  • Maryland
print profile

Alexis Reisin Miller
Partner


Email: armiller@morganlewis.com
Washington, D.C.
1111 Pennsylvania Ave., NW
Washington, DC 20004-2541
Phone: 202.739.5390
Fax: 202.739.3001

Alexis Reisin Miller is a partner in Morgan Lewis's FDA Practice. Ms. Miller focuses her practice primarily on regulatory issues pertaining to pharmaceuticals, medical devices, cosmetics, foods and dietary supplements, including product development, manufacturing, and marketing. Additionally, Ms. Miller has advised clients on regulatory issues relating to food and drug additives, and has experience with regulatory aspects of product liability litigation involving pharmaceutical products. She also counsels clients on the full array of regulatory issues affecting drug manufacturers and distributors in both pre- and post-market contexts.

Ms. Miller has experience in regulatory pathway and drug approval issues, pharmacovigilance reporting, and the regulation of drug and device labeling, advertising, and promotion by the FDA, including proprietary naming. Her experience also includes advising clients on Federal Trade Commission (FTC) consumer protection matters, including food, dietary supplement, cosmetic, and consumer product marketing, and Internet sales and related regulation. Ms. Miller also has provided extensive counsel to clients in matters before the Consumer Product Safety Commission (CPSC).

Prior to joining Morgan Lewis in 2011, Ms. Miller served as Regulatory Counsel to senior policy officials and science division directors at the FDA's Center for Drug Evaluation and Research. She also previously served as an associate in Morgan Lewis's FDA and Healthcare Practice from 2006 to 2010, during which she was seconded for extended periods of time to two large international pharmaceutical clients. Earlier in her career Ms. Miller also worked in-house, having served counsel at a Washington, D.C.-based biotechnology research and consulting firm.

Ms. Miller earned her J.D. from the Catholic University of America, Columbus School of Law in 2003 and her B.A., with honors, in international business and international relations from New York University in 1999. She is fluent in both written and spoken Spanish.

Ms. Miller is admitted to practice in the District of Columbia and Maryland. 

education

  • Catholic University of America, Columbus School of Law, 2003, J.D.
  • New York University, 1999, B.A., With Honors